HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Foghorn Therapeutics (NASDAQ:FHTX) and maintained a $20 price target.
June 28, 2023 | 4:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Foghorn Therapeutics' stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $20 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a $20 price target by HC Wainwright & Co. indicates their confidence in Foghorn Therapeutics' potential, which could positively impact the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100